Incidence and clinical characteristics in a Colombian cohort of ocular toxoplasmosis

Eye

Volumn 23, Issue 5, 2009, Pages 1090-1093

  De La Torre, A ^a   Lopez Castillo C A ^a   Gomez Marin J E ^a  

^a UNIVERSIDAD DEL QUINDÍO   (Colombia)

Author keywords

Colombia; Ocular toxoplasmosis; Recurrences; Retinochoroiditis; Uveitis

Indexed keywords

ADULT; ARTICLE; BLINDNESS; BLURRED VISION; CATARACT; CLINICAL FEATURE; COHORT ANALYSIS; COLOMBIA; EYE INJURY; EYE PAIN; EYE SYNECHIA; FEMALE; HEALTH CENTER; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHOTOPHOBIA; PROSPECTIVE STUDY; RETINA MACULA CYSTOID EDEMA; SEROLOGY; STRABISMUS; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLOMBIA; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STRABISMUS; TOXOPLASMA; TOXOPLASMOSIS, CONGENITAL; TOXOPLASMOSIS, OCULAR; YOUNG ADULT;

EID: 65949095011     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.219     Document Type: Article

References (13)

1. Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 2003; 136: 973-988.
2. de-la-Torre A, Gonzalez G, Diaz-Ramirez J, Gomez-Marin JE. Screening by ophthalmoscopy for Toxoplasma retinochoroiditis in Colombia. Am J Ophthalmol 2007; 143: 354-356.
3. Gómez JE, Castaño JC, Montoya MT. Toxoplasmosis congénita en Colombia: Un problema subestimado de salud pública. Colombia Médica 1995; 26: 66-70.
4. Gomez-Marin JE, delaTorre A. Positive benefit of postnatal treatment in congenital toxoplasmosis. Arch Dis Child 2007; 92: 88-89.
5. Zuluaga C, Sierra MV, Asprilla E. Causas de ceguera infantil en Cali. Colombia Medica 2005; 36: 25-238.
6. SYROCOT. Effectiveness of prenatal treatment for congenital toxoplasmosis: a metanalysis of individual patient's data. Lancet 2007; 369: 115-122.
7. Gomez Marin JE. New world and old world Toxoplasma: do they have a clinical relevance? Infectio 2007; S1: 26-28.
8. Holland GN, O'Connor GR, Belfort Jr R, Remington JS. Toxoplasmosis. In: Pepose JS, Holland GN, Wilhelmus KR (eds). Ocular Infection and Immunity. Mosby: St Louis, MO, 1996, pp 1183-1223.
9. Gilbert RE, Dunn DT, Lightman S, Murray PI, Pavesio CE, Gormley PD et al. Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. Epidemiol Infect 1999; 123: 283-289.
10. Bosch-Driessen L, Berendscho T, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology 2002; 109: 869-878.
11. Atmaca LS, Simsek T, Batioglu F. Clinical features and prognosis in ocular toxoplasmosis. Jpn J Ophthalmol 2004; 48: 386-391.
12. Soheilian M, Sadoughi MM, Ghajarnia M, Dehghan MH, Yazdani S, Behboudi H et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005; 112: 1876-1882.
13. Gomez-Marin JE, Montoya-De-Londono MT, Castano-Osorio JC, Heine FA, Duque AM, Chemla C et al. Frequency of specific anti-Toxoplasma gondii IgM, IgA and IgE in Colombian patients with acute and chronic ocular toxoplasmosis. Mem Inst Oswaldo Cruz 2000; 95: 89-94.